- Trials with a EudraCT protocol (71)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
71 result(s) found for: Combined oral contraceptive pill.
Displaying page 1 of 4.
EudraCT Number: 2007-005453-36 | Sponsor Protocol Number: MPC134 | Start Date*: 2009-02-19 | |||||||||||
Sponsor Name:Central and North West London NHS Foundation Trust (Camden Provider Services) | |||||||||||||
Full Title: The Effects of Standard vs. Tailored use of the Combined Oral Contraceptive on Continuation Rates at one year. | |||||||||||||
Medical condition: A randomised controlled trial to find out whether tailored pill use is better than standard pill use by seeing which approach leads to more women staying on the pill for at least one year. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000925-30 | Sponsor Protocol Number: 10 | Start Date*: 2013-05-04 | |||||||||||
Sponsor Name:Uppsala University | |||||||||||||
Full Title: How common are mood and sexual side-effects from combined oral contraceptives? | |||||||||||||
Medical condition: Healthy women | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007024-26 | Sponsor Protocol Number: BAY 86-5016/91557 | Start Date*: 2009-04-27 | ||||||||||||||||
Sponsor Name:Bayer Healthcare AG | ||||||||||||||||||
Full Title: A single-center, open-label, crossover, randomized study to investigate the impact of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestogene (material no. 8087... | ||||||||||||||||||
Medical condition: healthy volunteers | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003002-27 | Sponsor Protocol Number: MIT-Es001-C303 | Start Date*: 2020-10-14 | |||||||||||
Sponsor Name:Estetra SRL | |||||||||||||
Full Title: A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety, Compliance and Pharmacokinetics associated with the use of a Combined Oral Contraceptive Containing 15 mg Estetrol monohydrate an... | |||||||||||||
Medical condition: Contraception | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Female | ||||||||||||
Trial protocol: FI (Completed) EE (Completed) LV (Completed) SE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002263-13 | Sponsor Protocol Number: 91548 | Start Date*: 2009-03-13 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Multi-center, double-blind, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) compared to a monophasic contrace... | |||||||||||||
Medical condition: Reduced libido in women with acquired female sexual dysfunction (FSD) associated with oral contraceptive use. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000790-24 | Sponsor Protocol Number: BEC01 | Start Date*: 2020-07-14 | |||||||||||||||||||||
Sponsor Name:Universität Salzburg | |||||||||||||||||||||||
Full Title: BECONTRA - Effects of combined oral contraceptives on brain and behavior | |||||||||||||||||||||||
Medical condition: Girls and women 14 years - 35 years, considering the intake of COCs or under current use of EE/LNG or EE/CMA COCs | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003150-40 | Sponsor Protocol Number: MIT-Es0001-C301 | Start Date*: 2016-03-11 | |||||||||||
Sponsor Name:Estetra SPRL | |||||||||||||
Full Title: A Multicenter, Open-label, Single-Arm Study to Evaluate the Contraceptive Efficacy and Safety of a Combined Oral Contraceptive Containing 15 mg Estetrol and 3 mg Drospirenone | |||||||||||||
Medical condition: Contraception | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) SE (Completed) FI (Completed) PL (Completed) DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006633-41 | Sponsor Protocol Number: 310723 | Start Date*: 2007-04-11 | |||||||||||
Sponsor Name:Bayer Schering Pharma AG | |||||||||||||
Full Title: Monocenter, open-label, randomized study to determine the ovulation inhibitory effect of the combined oral contraceptives SH T04769G (0.015 mg Ethinylestradiol and 1.5 mg Dienogest in a modified re... | |||||||||||||
Medical condition: The aim of this monocenter, open-label, randomized study is to determine the ovulation inhibitory effect of the COC SH T04769G (0.15 mg Ethinylestradiol and 1.5 mg Dienogest in a modified release f... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005573-23 | Sponsor Protocol Number: 2914-015 | Start Date*: 2012-02-20 |
Sponsor Name:Laboratoire HRA Pharma | ||
Full Title: A prospective, randomized, double-blind parallel-arm, placebo-controlled study to assess the effects on ovarian activity of a combined oral contraceptive pill when preceded by the intake of ellaOne... | ||
Medical condition: Contraception | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Completed) NL (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-001658-14 | Sponsor Protocol Number: V920-012 | Start Date*: 2015-09-03 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co. Inc. | |||||||||||||
Full Title: A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lot Doses and a High Dose of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Ad... | |||||||||||||
Medical condition: Prevention of Ebola infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002208-26 | Sponsor Protocol Number: MK-8342B-062 | Start Date*: 2015-10-23 |
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc. | ||
Full Title: A Phase 3, randomized, active-comparator controlled clinical trial to study the contraceptive efficacy and safety of the MK-8342B (etonogestrel + 17β-estradiol) vaginal ring and the levonorgestrel-... | ||
Medical condition: Contraception | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NO (Completed) SE (Completed) DE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) AT (Completed) ES (Completed) NL (Completed) HU (Completed) PL (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-019945-24 | Sponsor Protocol Number: BEB-10 | Start Date*: 2010-09-24 |
Sponsor Name:Birken GmbH | ||
Full Title: Open, Prospective, Controlled Case series Documentation to Compare Intra-individually the Efficacy and Tolerance of Sericare versus Non-adhesive Wound Dressing alone in Accelerating the Epitheliali... | ||
Medical condition: This is an open, prospective, controlled case-series documentation to compare intra-individually the efficacy and tolerance of Sericare versus standard treatment in accelerating the epithelializati... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003372-31 | Sponsor Protocol Number: LJ401-BT01 | Start Date*: 2018-03-20 | |||||||||||
Sponsor Name:La Jolla Pharmaceutical Company | |||||||||||||
Full Title: A Multi-center, Randomized, Open-Label, Parallel-Group Study with LJPC-401 for the Treatment of Myocardial Iron Overload in Patients with Transfusion-Dependent Beta Thalassemia | |||||||||||||
Medical condition: Transfusion-dependent beta thalassemia with myocardial iron overload | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) CY (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004954-27 | Sponsor Protocol Number: | Start Date*: 2012-12-07 | |||||||||||
Sponsor Name:Clinical Trials and Research Governance, University of Oxford | |||||||||||||
Full Title: A single centre open-label randomised controlled trial of long term pituitary down-regulation before in vitro fertilisation for women with endometriosis: a pilot study | |||||||||||||
Medical condition: Sub-infertility due to endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001188-58 | Sponsor Protocol Number: IDIT001 | Start Date*: 2022-02-16 |
Sponsor Name:Göteborgs Universitet | ||
Full Title: The effect of anti-IL17 in new-onset type 1 diabetes: a randomized, double-blind, placebo-controlled trial | ||
Medical condition: Type 1 diabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2009-015743-16 | Sponsor Protocol Number: NA | Start Date*: 2009-10-09 |
Sponsor Name:University Hospitals of Leicester NHS Trust | ||
Full Title: A randomised, partially observer-blind, multi-centre, head-to-head comparison of a two dose regimen of Baxter and GSK H1N1 pandemic vaccines, administered 21 days apart | ||
Medical condition: Pandemic H1N1 influenza. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-003027-15 | Sponsor Protocol Number: EFFI2021/01 | Start Date*: 2023-03-20 | |||||||||||
Sponsor Name:ITALFARMACO S.P.A. | |||||||||||||
Full Title: A multicentre, prospective, open-label, non-comparative study to evaluate menstrual bleeding typology, tolerability, and compliance during a monophasic hormonal contraceptive treatment with norgest... | |||||||||||||
Medical condition: Combined Oral Contraceptives (COC) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001984-21 | Sponsor Protocol Number: 3/013/13 | Start Date*: 2013-09-11 | |||||||||||
Sponsor Name:University of Aberdeen & NHS Grampian | |||||||||||||
Full Title: PRE-EMPT: Preventing Recurrence of Endometriosis by Means of long acting Protestogen Therapy | |||||||||||||
Medical condition: Endometriosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020181-21 | Sponsor Protocol Number: BAY86-5028/13362 | Start Date*: 2011-01-13 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Multicenter, randomized, open-label, parallel-group study to evaluate user satisfaction with and tolerability of the low-dose levonorgestrel (LNG) intrauterine delivery system (IUS) with 12 µg LNG/... | |||||||||||||
Medical condition: The aim of the present study is to examine the overall satisfaction with and tolerability of LCS12 compared with a standard combined oral contraceptive (COC; Yasmin; 30 µg ethinyl estradiol and 3 m... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000550-12 | Sponsor Protocol Number: NRL920-01/2008 (IBSc) | Start Date*: 2008-11-06 | |||||||||||
Sponsor Name:Norgine Pharmaceuticals Ltd | |||||||||||||
Full Title: A Phase IIIb/IV, Multi-centre, Double-blind, Randomised, Placebo-controlled Parallel Group Study to Compare the Efficacy and Safety of Movicol® with Placebo in Patients with Constipation Associated... | |||||||||||||
Medical condition: Constipation associated with Irritable Bowel Syndrome (IBS-C). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) FR (Completed) IT (Completed) GB (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
